These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16532848)

  • 1. [Development of antisense nucleotides for therapy].
    Wang J; Wang L; Wang Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2006 Feb; 23(1):230-4. PubMed ID: 16532848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense therapy in malignant diseases: status quo and quo vadis?
    Tamm I
    Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotide therapy in cancer.
    Stephens AC; Rivers RP
    Curr Opin Mol Ther; 2003 Apr; 5(2):118-22. PubMed ID: 12772500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotides as therapeutic agents.
    Alama A; Barbieri F; Cagnoli M; Schettini G
    Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides: a new therapeutic approach.
    Temsamani J; Guinot P
    Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
    Sommer W; Heilig M
    Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotides and prevention of tumor growth: a different approach and proposal for a new method.
    Yildiz D; Oztas H; Hilal Ates B
    Med Hypotheses; 2005; 64(2):328-32. PubMed ID: 15607566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotide technology in the development of cancer therapeutics.
    Tseng BY; Brown KD
    Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prospects for antisense techniques].
    Zheng J; Tan T; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 1999 Dec; 16(4):516-9, 523. PubMed ID: 12552736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The significance of specific oligonucleotides in clinical medicine and their use in the treatment of patients with infective diseases].
    Bojić I
    Vojnosanit Pregl; 1996; 53(5):399-408. PubMed ID: 9229959
    [No Abstract]   [Full Text] [Related]  

  • 14. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells.
    Gao P; Zhou GY; Lei DP; Zhang XF; Li L; Xu JW; Lin XY
    Cytotherapy; 2007; 9(8):795-801. PubMed ID: 17917879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.
    Wagner A; Bock CT; Fechner H; Kurreck J
    Future Med Chem; 2015; 7(13):1637-42. PubMed ID: 26381598
    [No Abstract]   [Full Text] [Related]  

  • 16. Technology evaluation: GEM-231, Hybridon Inc.
    Blay J
    Curr Opin Mol Ther; 2000 Aug; 2(4):468-72. PubMed ID: 11249779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense technology and prospects for therapy of viral infections and cancer.
    Wagner RW; Flanagan WM
    Mol Med Today; 1997 Jan; 3(1):31-8. PubMed ID: 9021740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligonucleotide pharmacotherapy: an antigene strategy.
    Nagel KM; Holstad SG; Isenberg KE
    Pharmacotherapy; 1993; 13(3):177-88. PubMed ID: 8321732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense approaches to immune modulation for transplant and autoimmune diseases.
    Mourich DV; Marshall NB
    Curr Opin Pharmacol; 2005 Oct; 5(5):508-12. PubMed ID: 16087396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.